Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Lutetium-177 vipivotide tetraxetan - Advanced Accelerator Applications

Next Previous
Drug Profile

Lutetium-177 vipivotide tetraxetan - Advanced Accelerator Applications

Alternative Names: 177-Lutetium-PSMA-617 - Endocyte; 177Lu-EB-PSMA-617; 177Lu-PSMA; 177Lu-PSMA-617; 177LU-PSMA-617 - Endocyte; AAA617; Lu 177 vipivotide tetraxetan - Advanced Accelerator Applications; Lu177 RLT; Lutetium-177 PSMA 617; Pluvicto

Latest Information Update: 29 Jun 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Endocyte; RadioMedix
  • Developer Advanced Accelerator Applications; Australian and New Zealand Urogenital and Prostate Cancer Group; Australian Nuclear Science and Technology Organisation; Novartis
  • Class Amides; Amines; Antineoplastics; Aza compounds; Carboxylic acids; Cyclic hydrocarbons; Cyclohexanes; Drug conjugates; Naphthalenes; Radiopharmaceuticals
  • Mechanism of Action Ionising radiation emitters
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Prostate cancer

Most Recent Events

  • 22 Jun 2025 Phase-II clinical trials in Prostate cancer (Combination therapy, Hormone refractory, First-line therapy, Metastatic disease) in USA (IV) (NCT06894511)
  • 22 Jun 2025 Phase-II clinical trials in Prostate cancer (Monotherapy, Metastatic disease, Hormone refractory, First-line therapy) in USA (IV) (NCT06894511)
  • 02 Jun 2025 Novartis plans to file regulatory application for Prostate cancer (Combination therapy) (Hormone sensitive) in second half of 2025

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top